Analysis highlights the safety and effectiveness of glucagon-like peptide-1 receptor agonists in treating type 2 diabetes and obesity.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were approved by the FDA to treat type 2 diabetes (T2D) and to reduce the risk of major cardiovascular events in patients with T2D and known heart disease. With an alarming rise in T2D prevalence as well as its associated complications, the need for adequate treatment strategies for this chronic disease has never been higher. GLP-1 RAs have beneficial effects in treating T2D. This article discusses updates on the safety and effectiveness of GLP-1 RAs for obesity and many related conditions.
No takes yet. Share an insight, caveat, or question.
Browne-Bradwisch et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: